Thursday, May 29, 2014

The Motley Fool: Why Valeant's Offer Is Unlikely to Move the Needle

In the real world, if you ask a person out and they not only tell you "no" but then proceed to offer a multipage summary of all of your failings (at least in their eyes) and why they would be better off alone than with you, it's usually safe to say that it is time to move on. While corporate finance is part of the real world (allowing for liberal definitions of "real"), it certainly doesn't take the same view on rejection – while Allergan (NYSE: AGN  ) has, in so many words, told Valeant (NYSE: VRX  ) to drop dead and take its unsolicited offer with it, Valeant remains undeterred and has come back with yet another offer.

Read the full article here:
Why Valeant's Offer Is Unlikely to Move the Needle

No comments: